Sponsored By:

Pending Buy Signal Should Propel This Biotech to My Target

CELG has an excellent chance of breaking through its recent high

   

Celgene (CELG) — This company develops small molecule drugs for the treatment of blood-borne and solid-tumor cancers and inflammatory diseases. The stock was on my list of Top Stocks to Buy for December, near $164, and has been on the Trade of the Day buy list for over a year.

On Oct. 4, I said, “On Jan. 9, 2013, with CELG just above $ 91, I noted that S&P said it had ‘the brightest growth prospects among large-cap biotech companies.’ And on March 18, at $111.25, I pointed out that it had broken from a cup-and-handle formation with a target of $125.”

S&P has raised its 12-month target several times, recently boosting it to $208 from $188. It estimates earnings at $5.35 for 2013 and $6.66 in 2014 (an upgrade from $6.54).

Technically the stock is in a powerful bull channel with initial support at its 50-day moving average at $163. CELG can be volatile. The stock is arching up from its 50-day moving average, should shortly trigger a buy signal from MACD, and has an excellent chance of breaking the high at $174.66 and running to my trading target of $180.

Investors may want to buy CELG as a long-term investment in the biotech sector.

01 23 14 celg 300x191 Pending Buy Signal Should Propel This Biotech to My Target
Click to Enlarge

chart key 300x84 Pending Buy Signal Should Propel This Biotech to My Target


Article printed from InvestorPlace Media, http://investorplace.com/2014/01/trade-day-celgene-celg-2/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.